LLY - Eli Lilly and Company
| Previous Close | 107.90 |
| Open | 108.35 |
| Bid | 107.64 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 108.22 - 110.10 |
| 52 Week Range | 104.17 - 132.13 |
| Volume | 1,670,587 |
| Avg. Volume | 3,383,353 |
| Market Cap | 105.908B |
| Beta (3Y Monthly) | 0.25 |
| PE Ratio (TTM) | 13.84 |
| EPS (TTM) | 7.93 |
| Earnings Date | Oct 23, 2019 |
| Forward Dividend & Yield | 2.58 (2.39%) |
| Ex-Dividend Date | 2019-08-14 |
| 1y Target Est | 124.73 |
- Zacks
This is Why Eli Lilly (LLY) is a Great Dividend Stock
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
- GuruFocus.com
52-Week Company Lows
Eli Lilly and Co., DuPont de Nemours, Simon Property Group, EOG Resources, Occidental Petroleum, and Carnival Corp. Continue reading...
- Zacks
Lilly Gets FDA Approval for New Oral Tablets for Migraine
Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.
- Barrons.com
Eli Lilly Stock Gets 2 Pieces of Good News
The FDA approval of Eli Lilly’s migraine drug, Reyvow, and some promising data are giving Eli Lilly a lift.
- GuruFocus.com
New Sanofi CEO Looks to Shake Things Up
Paul Hudson is examining the organization from top to bottom with the goal of developing a strategy to put the company on the road to success Continue reading...
- PR Newswire
Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
INDIANAPOLIS, Oct. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demonstrating that 89 percent of patients treated with Taltz achieved a significant 75 percent improvement from baseline to Week 12 on their Psoriasis Area and Severity Index score (PASI 75) and 81 percent of patients treated with Taltz achieved a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1). Results of the study are being presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain.
- PR Newswire
Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval
INDIANAPOLIS, Oct. 11, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved REYVOW™ (lasmiditan) an oral medication for the acute treatment of migraine, with or without aura, in adults. REYVOW has a unique mechanism of action and is the first and only FDA-approved medicine in a new class of acute treatment for migraine (serotonin (5-HT)1F receptor agonists). "Millions of people with migraine face an ongoing battle with the unresolved pain and symptoms of a migraine attack.
- Reuters
UPDATE 1-Eli Lilly's migraine treatment wins U.S. FDA approval
The U.S. Food and Drug Administration said on Friday it had approved Eli Lilly and Co's migraine drug, Reyvow. The drug has been approved to treat acute migraine with or without aura, a sensory phenomenon or visual disturbance, in adults. Lilly acquired Reyvow, formerly called lasmiditan, in a deal https://www.reuters.com/article/us-colucid-pharms-m-a-eli-lilly-idUSKBN1521O6 worth about $960 million when it bought CoLucid Pharmaceuticals Inc in early 2017.
- Zacks
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
- Zacks
Gilead-Galapagos Report Efficacy & Safety Results on RA Drug
Gilead (GILD) announces 52-week efficacy and safety results on experimental RA drug, filgotinib, from two late-stage studies.
- Benzinga
The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra ...
- Insider Monkey
Here’s What Hedge Funds Think About Eli Lilly and Company (LLY)
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- Zacks
3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates
Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.
- Zacks
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.
- Zacks
Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study
Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema.
- GlobeNewswire
Verzenio™ (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study
Toronto, Oct. 09, 2019 -- Eli Lilly and Company (NYSE: LLY) announced that Verzenio™ (abemaciclib) in combination with fulvestrant significantly extended life by a median of.
- Zacks
Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan
Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.
- Reuters
UPDATE 2-Humira, Rituxan top list of U.S. drugs with biggest price increases -report
AbbVie Inc's rheumatoid arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. The price hikes were more than twice the rate of medical inflation and were not supported by any new clinical evidence, the Institute for Clinical and Economic Review (ICER) said in the analysis.
- Simply Wall St.
Can We See Significant Institutional Ownership On The Eli Lilly and Company (NYSE:LLY) Share Register?
The big shareholder groups in Eli Lilly and Company (NYSE:LLY) have power over the company. Large companies usually...
- PR Newswire
Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
Research from Taltz®, Olumiant® and mirikizumab highlight the impact Lilly's medicines may have for patients around the world INDIANAPOLIS , Oct. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) ...
- Zacks
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit
Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.
- Zacks
Novo Nordisk Focuses on Pipeline Development Amid Competition
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.
- PR Newswire
Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology
CYRAMZA, in combination with erlotinib, significantly delayed disease progression in previously untreated patients with metastatic non-small cell lung cancer whose tumors have activating EGFR mutations ...
- Yahoo Finance Video
Health savings accounts provide benefits, tax advantages
Rising health costs have become a burden for many Americans, but many people still may be unaware of one benefit they get, the health savings account. Personal finance expert Jean Chatzky joins Yahoo Finance to discuss the benefits of HSAs.
